Mch4 and mch5, apoptotic protease, nucleic acids encoding and methods of use
CA 2249233 C · Owner: Idun Pharmaceuticals, Inc. · Inventors: Tomaselli, Kevin; Litwack, Gerald; Alnemri, Emad S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof. The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch4 or Mch5 nucleotide sequences. Also provided are genes and nucleic acids encoding functional fragments such as the FADD-like domains Mch4A Mch4B, Mch5A and , Mch5B. Isolated Mch4 or Mch5 polypeptides or functional fragments thereof including the FADD-like domains Mch4A, Mch4B Mch5A and Mch5B are also , provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 19, 1997 and granted May 22, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 19, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 19, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.